Community Action Agency of Siouxland providing food assistance to daycares
SIOUX CITY, Iowa (KCAU) — Daycare providers are being offered food assistance by a local nonprofit agency.
The National Child and Adult Care Food Program is a federal program that pays for healthy meals and snacks for children and adults in daycare. The Community Action Agency of Siouxland administers the program locally, but says only 38 out of 91 eligible child care providers in Woodbury County have actively participated.
Lineworkers hard at work restoring power to Siouxland
'There are 53 daycare providers just in Woodbury County alone that are not taking advantage of this program, and we feel like it's a great, great program and it helps pay for, helps reimburse the cost of meals and snacks that the daycare provider would serve in their home,' Community Action Agency of Siouxland Executive Director Jean Logan said. 'So it's win-win, really.'
Any daycare providers interested in joining this program can learn more by .
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
35 minutes ago
- Business Wire
Debiopharm and Alkyon Therapeutics Announce Research Collaboration to Advance the Next Generation of Radioligand Therapies
MARTIGNY, Switzerland & LAUSANNE, Switzerland & SAN DIEGO--(BUSINESS WIRE)--Debiopharm ( a privately-owned Swiss biopharmaceutical company committed to establishing tomorrow's standard of care to cure cancer and infectious diseases and Alkyon Therapeutics, Inc., a biotechnology company pioneering precision-targeted therapies, today announced the signing of a co-research agreement to evaluate the feasibility of developing targeted radioligand therapies (RLTs) using Debiopharm's proprietary AbYlink™ conjugation technology for Alkyon's modular antibody platform directed against undisclosed tumor-associated antigens. This collaboration marks a promising step toward a new generation of RLTs designed to deliver potent radiation targeted directly to cancer cells while minimizing damage to healthy tissues. By leveraging the unique strengths of both platforms, the goal is to create more effective, better-tolerated cancer treatments that improve patient quality of life and expand therapeutic options for difficult-to-treat tumors. AbYLink™ technology enables regio-selective lysine conjugation, ensuring the radioligand avoids the target binding site and facilitating streamlined, consistent manufacturing. 'We're intrigued to explore the potential of applying AbYlink™ conjugation technology to the radio-oncology field,' expressed Frederic Levy, Chief Scientific Officer, Debiopharm. 'Leveraging our innovative conjugation platform with Alkyon's engineered antibody scaffolds could open new possibilities for next-generation radiopharmaceuticals with enhanced precision and therapeutic impact.' 'This collaboration reflects our shared commitment to expanding the potential of radioligand therapies,' said Benjamin Titz, Co-Founder and CEO of Alkyon Therapeutics. 'By applying AbYlink™ to our specialized antibody scaffolds and targeting strategies tailored to the unique architecture of solid tumors, we aim to unlock new therapeutic possibilities and advance care for patients with difficult-to-treat solid tumors.' About AbYlink™ AbYlink™ is a versatile and rapid regio-selective chemical conjugation technology for use in preparing diagnostic or therapeutic conjugates. This one-step method results in stable conjugation at defined and invariable sites on the Fc domain of an antibody or the like, with no impact on antigen-binding regions. It enables a seamless and reproducible conjugation of payloads (e.g., a chelator for radiolabeling, a fluorescent dye or a drug) to antibodies or ADCs. The universal applicability of the technology has been demonstrated for various antibody isotypes and payloads. About Alkyon Therapeutics, Inc. Alkyon Therapeutics, Inc. (AlkyonTx™) is a biotechnology company developing next-generation radioligand therapies (RLTs) for solid tumors. By combining precision-engineered antibodies with advanced radiochemistry and dosimetry technologies, Alkyon aims to overcome barriers such as immune exclusion and drug resistance in difficult-to-treat cancers. Its modular platform supports monotherapies, bispecifics, and rational combinations designed to enable differentiated clinical benefit and scalable product development. Debiopharm's commitment to patients Debiopharm aims to develop innovative therapies that target high unmet medical needs primarily in oncology and bacterial infections. Bridging the gap between disruptive discovery products and real-world patient reach, we identify high-potential compounds and technologies for in-licensing, clinically demonstrate their safety and efficacy, and then hand stewardship to large pharmaceutical commercialization partners to maximize patient access globally. For more information, please visit
Business Wire
40 minutes ago
- Business Wire
Ionis announces Dr. Richard Geary, chief development officer, to retire; Dr. Holly Kordasiewicz to assume role in January 2026
CARLSBAD, Calif.--(BUSINESS WIRE)-- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that Richard Geary, Ph.D., executive vice president and chief development officer, will retire effective January 2026 and that Holly Kordasiewicz, Ph.D., currently senior vice president, neurology, will succeed him in the role. 'Richard has made tremendous contributions to Ionis over his 30-year tenure during which he spearheaded dozens of development programs and brought six innovative medicines through regulatory approvals, including TRYNGOLZA, our first independent commercial medicine. We thank him for his leadership and unwavering dedication to patients in need,' said Brett P. Monia, Ph.D., chief executive officer, Ionis. 'Holly is a deeply respected and innovative leader who will champion our vision to bring a steady cadence of transformational medicines to people in need and support Ionis' continued growth as a fully integrated biotechnology company. Her broad experience across research and development, strong operational and management skills, and deep neurology expertise, position Holly to successfully guide our portfolio, which includes eight wholly owned neurology medicines in clinical development.' Dr. Kordasiewicz has 20 years of experience in research and development and joined Ionis in 2011. An expert in neurology drug development, she currently oversees Ionis' industry-leading neurology program, including medicines for Alexander disease, Angelman syndrome, Alzheimer's disease, prion disease and multiple system atrophy. Dr. Kordasiewicz also played an integral role in the discovery and development of our Biogen-partnered programs QALSODY ® (tofersen) for a genetic form of amyotrophic lateral sclerosis and IONIS-MAPT Rx (BIIB080), a promising Alzheimer's disease medicine in Phase 2 development. Dr. Kordasiewicz holds a B.A. from SUNY-Geneseo and a Ph.D. in Neuroscience from the University of Minnesota. She completed postdoctoral work at the University of Minnesota and the University of California San Diego. Dr. Geary joined Ionis in 1995 and has been involved in nearly every aspect of discovery and development. Under Dr. Geary's leadership, Ionis submitted more than 50 investigational new drug applications to regulatory agencies and achieved six FDA and EU approvals, including TRYNGOLZA ® (olezarsen). Dr. Geary will serve as a strategic consultant to Ionis throughout 2026 to support a seamless transition. About Ionis Pharmaceuticals, Inc. For three decades, Ionis has invented medicines that bring better futures to people with serious diseases. Ionis currently has six marketed medicines and a leading pipeline in neurology, cardiology and select areas of high patient need. As the pioneer in RNA-targeted medicines, Ionis continues to drive innovation in RNA therapies in addition to advancing new approaches in gene editing. A deep understanding of disease biology and industry-leading technology propels our work, coupled with a passion and urgency to deliver life-changing advances for patients. To learn more about Ionis, visit and follow us on X (Twitter), LinkedIn and Instagram. Ionis Forward-looking Statements This press release includes forward-looking statements regarding Ionis' business and the therapeutic and commercial potential of our commercial medicines, additional medicines in development and technologies. Any statement describing Ionis' goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties including those inherent in the process of discovering, developing and commercializing medicines that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such medicines. Ionis' forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements. Although Ionis' forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Ionis. Except as required by law, we undertake no obligation to update any forward-looking statements for any reason. As a result, you are cautioned not to rely on these forward-looking statements. These and other risks concerning Ionis' programs are described in additional detail in Ionis' annual report on Form 10-K for the year ended December 31, 2024, and most recent Form 10-Q, which are on file with the Securities and Exchange Commission. Copies of these and other documents are available from the Company. In this press release, unless the context requires otherwise, "Ionis," "Company," "we," "our" and "us" all refer to Ionis Pharmaceuticals and its subsidiaries. Ionis Pharmaceuticals ® and TRYNGOLZA ® are trademarks of Ionis Pharmaceuticals, Inc. QALSODY ® is a registered trademark of Biogen.
Yahoo
44 minutes ago
- Yahoo
Iowa Gov. Reynolds signs bill to reform pharmacy benefit managers
DES MOINES, Iowa (KCAU) — Iowa Gov. Kim Reynolds signed a bill Wednesday aimed at bringing changes to pharmacy benefit managers, also known as PBMs. The legislation, Senate File 383, aims to help prevent more independent and rural pharmacies from closing their doors in the Hawkeye State. PBMs are the middlemen between health insurance companies and pharmacies. Whenever you fill a prescription, the PBM determines how much the pharmacy actually gets paid for dispensing your medication. Iowa governor rejects GOP bill to increase regulations of Summit's carbon dioxide pipeline In recent years, that amount has sometimes been less than what it costs the pharmacy to fill a prescription, forcing them to either refuse the fill, or take a financial loss. Senate File 383 would attempt to prevent that by adding requirements for how much pharmacies must be reimbursed for filling medications, to ensure they get paid a fair price. It also adds other patient protections, like preventing PBMs from hitting you with a monetary penalty if you choose a non-preferred pharmacy, or requiring you to use a mail-order pharmacy service to use your insurance coverage. As of Wednesday, a total of 32 states have passed similar legislation, according to the Iowa Governor's Office. Opponents of the measure have argued the bill would increase health insurance premiums, but supporters maintain that in states that have previously passed similar legislation, that has not come to pass. Governor Reynolds released a statement Wednesday explaining her reasoning for signing the bill. In part, it says, 'The new bill takes steps toward addressing these challenges by targeting PBM practices that harm both patients and independent pharmacies. Local pharmacies, especially in rural areas, are vital to community health and local hospitals but are being driven out by opaque, one-sided contracts.' You can read the governor's full statement here. The Iowa Pharmacy Association applauded the bill's passage Wednesday. CEO Kate Gainer said, 'Governor Reynolds' leadership and the Iowa Legislature's bipartisan support of SF 383 sends a powerful message that the health of Iowa communities comes first. For too long, PBMs have put profits over patients, contributing to the closure of more than 200 pharmacies in Iowa since 2014. This law gives us the tools to level the playing field and protect access to care, especially in rural areas.' Story continues below Top Story: Recent incident at Sac County Jail highlights need for new facility Lights & Sirens: Suspect shot at during pursuit in stolen vehicle, Dakota Co Sheriff says Sports: West Sioux boys soccer wins first-ever IHSAA State title with 2-1 OT win Weather: Get the latest weather forecast here The Iowa Association of Business and Industry, however, opposed the bill's signing, releasing a statement saying, 'ABI is disappointed in today's action. ABI testified at every turn in favor of legislation that would support small independent pharmacies in Iowa. The bill that the Governor signed today is not that. Senate File 383 includes expensive, unneeded provisions that are going to drive up the costs of pharmacy services in Iowa without any discernable improvement in patient care. Iowans – including businesses and employees – will bear these costs at the pharmacy counter and in the structure of their health care plans. This is an additional headwind in an already challenging business environment. Now law, ABI will take every opportunity to mitigate the increased costs on our members and their team members throughout Iowa.' Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
